熱門資訊> 正文
赛诺菲完成对Kadmon的收购
2021-11-09 23:04
10:04 AM EST, 11/09/2021 (MT Newswires) -- Sanofi (SAN.PA) on Tuesday completed the acquisition of US biopharmaceutical company Kadmon for a total equity value of around $1.9 billion. The acquisition took place as a merger of Sanofi's unit with and into Kadmon. After the merger, Kadmon remains the surviving company and becomes a subsidiary of Sanofi. Shares of the pharmaceutical company were up 1% on Tuesday afternoon.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
